Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005977 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
A Phase 3 study of Lymphoma and Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT00005977: Completed Phase 3 study of Lymphoma and Leukemia, sponsored by Children's Oncology Group.
NCT00005977 is a Phase 3 study of Lymphoma and Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 83 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005977, a Phase 3 study of Lymphoma and Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Primary Outcome
Assess the effect of high dose methotrexate in combination with standard treatment per the POG 9317 protocol on 1-year event-free survival (EFS), monitor and assess toxicity, and estimate the hospitalization costs for the treatment of toxicity related side effects.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
Study Locations (20)
California
- University of California San Diego Cancer Center - La Jolla
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- Sutter Cancer Center - Sacramento
- University of California Davis Medical Center - Sacramento
- Kaiser Permanente-Southern California Permanente Medical Group - San Diego
- Children's Hospital and Health Center - San Diego
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
Florida
- Broward General Medical Center - Fort Lauderdale
- Children's Hospital of Southwest Florida - Fort Myers
- Shands Hospital and Clinics, University of Florida - Gainesville
- Nemours Children's Clinic - Jacksonville
- Sylvester Cancer Center, University of Miami - Miami
- University of Miami-Jackson Memorial Hospital Medical Center - Miami
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- University of South Alabama Medical Center - Mobile
- MBCCOP - Gulf Coast - Mobile
Arizona
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Yale Comprehensive Cancer Center - New Haven
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2000-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00005977 record still lists
NCT00005977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005977 names 20 study sites across 7 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00005977 about?
NCT00005977 is a clinical study titled "Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have non-Hodgkin'...
What is the current status of trial NCT00005977?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2000-09. Estimated completion is 2006-09.
What conditions does trial NCT00005977 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00005977?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00005977?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005977 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005977's enrollment target sits among peer trials
83 101st of 299 higher than 198 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
- NCT05419089 · 83 participants · Phase 2
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia